Streetbeat News

SPRY

ARS Pharmaceuticals, Inc.

Industry

Biotechnology

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

Open

12.30

Mkt cap

1.4B

Volume

8.8M

High

15.09

P/E Ratio

-28.62

52-wk high

18.51

Low

12.28

Div yield

N/A

52-wk low

7.55

ARS Pharmaceuticals reported robust Q4 and full-year 2024 earnings, with significant stock price appreciation driven by their needle-free epinephrine treatment, neffy. The company's promising market potential has attracted investor attention and positively impacted stock performance.

Portfolio Pulse from

March 20, 2025 | 7:45 pm

ARS Pharmaceuticals held its Q4 2024 earnings conference call, discussing corporate progress, the launch of their product Neffy, and commercial strategy. Key executives including CEO Richard Lowenthal and Chief Commercial Officer Eric Karas were present to provide insights into the company's performance and future plans.

Portfolio Pulse from

March 20, 2025 | 5:45 pm

ARS Pharmaceuticals, Inc. (SPRY) reported Q4 earnings of $0.52 per share, surpassing the Zacks Consensus Estimate of a loss of $0.04 per share. This marks a significant improvement from the loss of $0.07 per share a year ago.

Portfolio Pulse from

March 20, 2025 | 1:45 pm

ARS Pharmaceuticals reported $7.3 million in U.S. net product revenue for its epinephrine nasal spray, neffy®, since its launch in late September 2024. The financial results cover the fourth quarter and full year of 2024.

Portfolio Pulse from

March 20, 2025 | 11:15 am

ARS Pharmaceuticals reported $7.3 million in U.S. net product revenue for its neffy® (epinephrine nasal spray) since its launch in late September 2024. The financial results cover the fourth quarter and full year of 2024.

Portfolio Pulse from

March 20, 2025 | 11:15 am

ARS Pharmaceuticals has received FDA approval for neffy® 1 mg, a needle-free epinephrine nasal spray for treating Type I allergic reactions, including anaphylaxis, in pediatric patients weighing 15 to < 30 kilograms. This marks the first approval of such a treatment for younger children.

Portfolio Pulse from

March 05, 2025 | 9:30 pm

ARS Pharmaceuticals will present data on their epinephrine nasal spray, neffy, at the 2025 AAAAI Annual Meeting. Studies show neffy is effective and safe for managing anaphylaxis, offering a needle-free alternative to traditional treatments.

Portfolio Pulse from

February 18, 2025 | 1:15 pm

ARS Pharmaceuticals has launched Neffy, the first FDA-approved needle-free epinephrine nasal spray for severe allergic reactions. Early sales have exceeded expectations, indicating its potential as a blockbuster product. Neffy targets multiple segments within severe allergic reactions and may become an OTC medication, representing a multibillion-dollar total addressable market.

Portfolio Pulse from

February 06, 2025 | 6:15 am

ARS Pharmaceuticals has announced that its product, neffy® (Epinephrine Nasal Spray), is now available on Express Scripts Commercial National Formularies as of November 22, 2024. This inclusion expands access for patients and caregivers managing Type 1 Allergic Reactions.

Portfolio Pulse from

December 19, 2024 | 10:45 pm

ARS Pharmaceuticals has announced that its licensing partners have filed for approval of neffy, an epinephrine nasal spray, in China, Japan, and Australia. This marks a significant step in expanding the product's availability in the Asia Pacific region.

Portfolio Pulse from

December 12, 2024 | 7:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.